Home » Posts tagged with » Cambridge
Pandion bags $795m deal with Astellas for pancreas-targeted immunomodulators

Pandion bags $795m deal with Astellas for pancreas-targeted immunomodulators

Pandion Therapeutics has bagged a $795 million worth license and collaboration deal with Japanese pharma company Astellas Pharma for the research, development, and commercialization of locally acting immunomodulators targeting autoimmune diseases of the pancreas. The collaboration will bring together the modular biologics and functional immunology expertise of Cambridge-based biotech company and Astellas Pharma’s advanced therapeutics […]

Jazz Pharmaceuticals acquires Cavion, developer of essential tremor drugs

Jazz Pharmaceuticals acquisition of Cavion : Irish pharma company Jazz Pharmaceuticals has acquired US-based clinical-stage pharma company Cavion, a developer of essential tremor drugs, in a deal worth up to $312.5 million as per the latest pharma acquisition news. Based in Cambridge, Massachusetts, Cavion is engaged in developing therapies aimed at regulating the T-type calcium […]

Continue reading …
Bayer to fully acquire US cell therapy company BlueRock Therapeutics

Bayer acquisition of BlueRock Therapeutics : Bayer will take full ownership in US cell therapy company BlueRock Therapeutics for an enterprise value of up to $1 billion, as per the latest pharma acquisition news. Headquartered in Cambridge, BlueRock Therapeutics develops engineered cell therapies in the fields of neurology, cardiology, and immunology using its proprietary induced […]

Continue reading …
X4 Pharmaceuticals wraps up merger with Arsanis

X4 Pharmaceuticals has completed its previously announced merger with Arsanis in a move to create a late-stage biopharma company focused on rare diseases and cancer. Both companies are based in Massachusetts. X4 Pharmaceuticals is engaged in developing drugs designed to boost immune cell trafficking for the treatment of rare diseases that include primary immunodeficiencies and […]

Continue reading …
Blackstone Life Sciences, Novartis launch Anthos Therapeutics

Blackstone Life Sciences, a private investment platform, has joined forces with Swiss drug maker Novartis to launch a new biopharma company called Anthos Therapeutics, which will focus on developing drugs for high-risk cardiovascular patients. Anthos Therapeutics, which will be headquartered in Cambridge, Massachusetts, is backed by a capital of $250 million from Blackstone Life Sciences. […]

Continue reading …
SIRION Biotech opens new office in Massachusetts

CAMBRIDGE, Mass.–(BUSINESS WIRE)–SIRION Biotech International Inc., a wholly-owned subsidiary of SIRION Biotech GmbH in Germany (“SIRION”), offering the most comprehensive portfolio of custom viral vectors for preclinical and clinical studies, today announced the grand opening of a new office at 125 Cambridgepark Drive, Suite 301, Cambridge, Massachusetts 02140. SIRION was pleased to meet its new neighbors last night […]

Continue reading …
Tamr joins Accenture’s life sciences ecosystem to help drive innovation in drug discovery and scientific research

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Tamr Inc. today announced it has joined Accenture’s open partner ecosystem, designed to help independent software vendors (ISVs) and life science companies team more effectively to accelerate drug discovery efforts and improve patient outcomes. The ecosystem is an integral part of Accenture’s cloud-based informatics research platform, which has been designed to help life sciences organizations […]

Continue reading …
New US biotech company Twentyeight-Seven Therapeutics launched with $65m funding

A new US biotech company called Twentyeight-Seven Therapeutics (28-7) has been launched in Cambridge, which will focus on modulating non-coding RNA (ncRNA) biology to develop therapies for cancer and other diseases. Twentyeight-Seven Therapeutics has raised $65 million in a Series A financing round coinciding with its launch with founding investor MPM Capital and Novartis Venture […]

Continue reading …